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Abstract
Objective: To evaluate the cost-effectiveness of radical prostatectomy (RP), external beam radiotherapy
(EBRT) monotherapy, and EBRT+brachytherapy for men with very high-risk prostate cancer (VHRPC).
Methods: Using a decision tree with embedded Markov process models, a cost-utility analysis was
performed comparing the three treatment strategies for hypothetical cohorts of men with VHRPC. The
base case time horizon was ten years; consistent with the maximum follow-up reported in the literature.
The model parameters for distant metastases and mortality were derived from a multi-institutional study
utilizing patient-level data. Costs were from a societal standpoint and health state utilities were obtained
via standard gamble techniques. Incremental cost-effectiveness ratios were calculated per qualityadjusted life year using a 3% discount rate. Sensitivity analyses (SA) addressed uncertainty in key
variables. Findings: EBRT+brachytherapy was both cost-saving and more effective than both EBRT
monotherapy and RP, strongly dominating both alternative treatment strategies. These results remained
robust to extensive SA.
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ABSTRACT

Objective: To evaluate the cost-effectiveness of radical prostatectomy (RP), external beam
radiotherapy (EBRT) monotherapy, and EBRT+brachytherapy for men with very high-risk
prostate cancer (VHRPC).

Methods: Using a decision tree with embedded Markov process models, a cost-utility analysis
was performed comparing the three treatment strategies for hypothetical cohorts of men with
VHRPC. The base case time horizon was ten years; consistent with the maximum follow-up
reported in the literature. The model parameters for distant metastases and mortality were
derived from a multi-institutional study utilizing patient-level data. Costs were from a societal
standpoint and health state utilities were obtained via standard gamble techniques. Incremental
cost-effectiveness ratios were calculated per quality-adjusted life year using a 3% discount rate.
Sensitivity analyses (SA) addressed uncertainty in key variables.

Findings: EBRT+brachytherapy was both cost-saving and more effective than both EBRT
monotherapy and RP, strongly dominating both alternative treatment strategies. These results
remained robust to extensive SA.
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INTRODUCTION
The American Cancer Society has estimated that nearly 192,000 new cases of
adenocarcinoma of the prostate will be diagnosed in 2020, an increase of five percent from the
prior year (American Cancer Society 2020). Prostate cancer is also expected to account for over
33,000 deaths and will top the 2020 list of male cancer diagnoses at 21 percent with its closest
competitor being lung cancer at only 13 percent. Twenty-five percent of these men present with
high-risk disease, defined as cancers with high-grade pathology by the Gleason scoring system,
i.e. Gleason scores of 8-10 out of 10 or a serum prostate specific antigen level greater than 20
ng/mL (Parikh and Sher 2012). Further stratifying risk, seven to ten percent of all prostate cancer
patients present with very high-risk disease with Gleason scores of 9 or 10, a particularly
aggressive variant with a propensity for distant metastases and a high probability of prostate
cancer-related death (Kishan et al. 2018).
The optimal management of very high-risk prostate cancer has remained unclear but
typically has involved the following three state-of-the art treatment options, supported by
national standards of care: 1) robotic-assisted laparoscopic prostatectomy (RALP), i.e. surgical
removal of the prostate with a pelvic lymph node dissection; 2) external beam radiotherapy
(EBRT) monotherapy via image-guided intensity modulated radiotherapy (IG-IMRT) involving
20 to 45 daily treatments, Monday through Friday; and 3) EBRT over 15 to 28 treatments
followed by one or two transperineal brachytherapy (radioactive seed) interstitial implants,
facilitating intense dose escalation to the prostate either via low dose rate radioisotopes such as
Iodine-125 or high dose rate (HDR) radioisotopes such as Iridium-192 (National Comprehensive
Cancer Network 2020). Both radiotherapy options are usually combined with 18 to 24 months of
androgen deprivation therapy, which has been shown to improve survival in men with high-risk
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disease (National Comprehensive Cancer Network 2020). Which of these three contemporary
treatments for very high-risk prostate cancer provides the best outcomes remains unclear and this
question has not been studied in any randomized controlled clinical trial. In a multi-institutional
collaborative effort to more definitively evaluate the optimal treatment strategy for this very
high-risk prostate cancer cohort, Kishan et al. (2018) recently reported the results of a
retrospective cohort study of 1,809 patients with Gleason score 9-10 prostate cancer utilizing the
individual patient data from 11 tertiary referral centers in the United States and one in Norway.
At a median follow up ranging from 4.2 to 6.3 years for the three treatment groups, the
combination EBRT plus brachytherapy boost group was shown to have a statistically significant
improvement in prostate cancer-specific survival and a lower risk of distant metastases than
either the EBRT monotherapy or RALP groups.
In an environment of limited health care resources and with United States (US) national
expenditures for prostate cancer care projected to reach over $20 billion in 2020, decisionmaking authorities will increasingly require information on the cost-effectiveness of alternative
treatment paradigms such as RALP, EBRT monotherapy and EBRT plus brachytherapy in order
to inform health policy (Marriotto et al. 2011). The nontrivial differences in costs, efficacy and
quality-of-life effects associated with the various treatment strategies to manage very high-risk
prostate cancer suggest that quantifying the cost-effectiveness of these different treatment
protocols is important. The purpose of this study was to evaluate the cost-effectiveness of RALP,
EBRT monotherapy, and EBRT plus brachytherapy for patients with very high-risk prostate
cancer based on the results of Kishan et al. (2018).

METHODS
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Overview
In health care economies with limited budgets, cost-effectiveness analysis provides an
analytical framework to compare the net benefit of a particular intervention to those benefits that
others must forfeit as a result of reallocating resources. Cost-utility analysis considers the
difference in incremental costs and quality-of-life-adjusted survival among treatment programs
being considered, reported as the incremental cost-effectiveness ratio (ICER), which is compared
to a willingness-to-pay threshold, usually determined by society or payers, and measured in
dollars per additional quality-adjusted life year (QALY) gained. This represents the health
benefits that may be given up by others due to any additional costs associated with a particular
program.

Decision Model
Using TreeAge Pro software (Williamstown, MA), a decision tree with three embedded
Markov models was developed to estimate the QALYs and the direct medical and non-medical
costs associated with the three very high-risk prostate cancer treatment strategies from a societal
perspective (Figure 1). As recommended by Levine, Ganz, and Haller (2007), the base-case time
horizon of the cost-utility analysis was ten years, consistent with the maximum follow-up
reported by Kishan et al. (2018) and not on results projected into the future. The Markov cycle
length was set at six months to be temporally in line with the clinical treatment paradigms being
evaluated.

Markov Models
Markov simulations track patient transitions among mutually exclusive health states at
fixed time cycles according to input probabilities. During each cycle, patients accumulate costs
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and QALYs (Sonnenberg and Beck 1993). The patient cohort entered the model in the Alive
Without Distant Metastasis (AWODM) health state and transitioned among health states of Alive
With Distant Metastases (AWDM), Dead from Prostate Cancer and Dead from Other Causes,
based on probabilities derived from Kishan et al. (2018) (Table 1).

Survival Data and Analytic Methods
A single study-based estimate of effectiveness was used because Kishan et al. (2018) is
the largest published multi-institutional study to evaluate the comparative effectiveness of
RALP, EBRT monotherapy and EBRT plus brachytherapy for patients with Gleason score 9-10
prostate cancer treated according current national guidelines (National Comprehensive Cancer
Network 2020). The adjusted five- and ten-year cumulative incidences for distant metastases,
prostate-cancer specific mortality and all-cause mortality were used. These incidences were
derived using Kaplan-Meier estimates with inverse probability of treatment weights for the
intervals of years one through five years and six through ten, determined by utilizing propensity
scores calculated with multinomial logistic regression with each treatment group set as the
outcome and prostate-specific antigen level, age, cancer stage, and Gleason score as pretreatment
prognostic covariates (Table 1). It was assumed that mortality from causes other than prostate
cancer was equal to all-cause mortality minus prostate-cancer-specific mortality for the years one
through five and six through ten cumulative estimates. The probabilities for each 5-year time
interval were converted to 6-month rates using the formula rate = -ln(1-p)/t, where p equals the
probability and t equals time. The six-month rate was then converted back to a six-month
probability to coincide with the selected Markov cycle length using the formula, probability = 1-
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e(-rt), where r equals rate and t equals time. The model was then calibrated to accurately match the
mortality and distant metastases risks reported in the study (Kishan et al. 2018).

Direct Medical and Non-Medical Costs
Consistent with a societal perspective, both direct medical and non-medical costs were
considered. If necessary, costs were inflated to 2019 US dollars using the medical care
component of the US Chained Consumer Price Index (United States Bureau of Labor Statistics
2020).
Direct medical costs for the AWODM health state of the EBRT monotherapy and EBRT
plus brachytherapy treatment cohorts were obtained from the Centers for Medicare and Medicaid
Services Physician Fee Schedule national payment amount and are shown in Tables 2 and 3
(Centers for Medicare & Medicaid Services 2020). For any radiotherapy treatment group, these
costs included a comprehensive-level consultation with a radiation oncologist, treatment
simulation and planning, dosimetry, ongoing physics support, treatment delivery, and weekly
patient management. Patients in the EBRT monotherapy group were treated with a moderately
hypofractionated EBRT program using IG-IMRT to a total dose of 60 Gy in 20 fractions of 3 Gy
each, delivered on a five days per week schedule. Those in the EBRT plus brachytherapy group
received EBRT in a similar fashion but to a final dose of 37.5 Gy in 15 fractions of 2.5 Gy each
delivered five days per week followed by a single HDR Ir-192 brachytherapy treatment of 15
Gy. It was assumed that half of the brachytherapy cohort would undergo the implant at a
hospital-based outpatient surgery department and half at an ambulatory surgery center in order to
capture the cost differences associated with these diverse points of care (Hall, Schwartzman,
Zhang, and Liu 2017). Based on National Comprehensive Cancer Network (NCCN) guidelines,
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all patients in the two radiotherapy treatment groups received a total of 24 months of androgen
deprivation therapy by intramuscular leuprolide injections delivered on a once every three-month
schedule (Table 4). The direct medical costs of RALP were obtained from a retrospective, crosssectional study of hospital discharges based on national inpatient sample data of the Healthcare
Cost and Utilization Project (HCUP), using Medicare reimbursement adjusted by the appropriate
cost-to-charge ratios published by HCUP (Mukherjee 2019). As per Kishan et al. (2018), 33.3
percent of the RALP cohort received androgen deprivation therapy, which was assumed to
consist of a total of six months of leuprolide, consistent with NCCN guidelines (National
Comprehensive Cancer Network 2020). In addition, 42.8 percent of the RALP group received
adjuvant or salvage EBRT (Kishan et al. 2018). Adjuvant/salvage EBRT was carried out using
conventional fractionation and consisted of a total dose of 70 Gy delivered in 35 fractions of 2
Gy each on a Monday through Friday schedule with the associated direct medical costs shown in
Table 5 (National Comprehensive Cancer Network 2020). The direct medical costs of RALP
incurred during the first Markov cycle were $28,822; i.e., $18,974 for the procedure plus $9,400
and $447 for the proportions of the cohort receiving adjuvant/salvage EBRT and androgen
deprivation therapy, respectively.
The direct medical costs for the AWDM health state are shown in Table 6 and were
derived from a deterministic, decision analytic model that estimated the direct medical costs
associated with the management of prostate cancer including metastatic disease from a US
commercial-payer perspective (Gustavsen, Gullet, Cole, Lewine, and Bishoff 2019). In order to
account for the differences in costs between patients with castrate-naïve disease, which is still
responsive to androgen deprivation therapy, and castrate-resistant disease, which is resistant to
androgen deprivation therapy and more expensive to manage, the total direct medical costs for
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the AWDM were weighted by the proportion of patients with either castrate-naïve or castrateresistant metastatic prostate cancer (Sathianathan 2019). The costs associated with follow-up
testing and office visits after definitive treatment are the same for all three treatment strategies
and therefore, were not modelled (National Comprehensive Cancer Network 2020). Other
potential downstream costs to manage potential late complications of each treatment modality
were not considered since there is a paucity of data to accurately compare longer-term toxicities
of these three treatment approaches in the modern era using state-of-the art treatment
technologies (Yu and Hamstra 2017).
Direct non-medical costs were estimated for patient transportation and patient-related
time lost from productive work or leisure associated with treatment and office visits (Table7).
Direct non-medical costs of patient transportation for treatments included the average number of
miles traveled to receive care and parking (Longacre, Neprash, Shippee, Tuttle, and Virnig 2019;
Inrix 2017). Travel costs for any treatment-related visit were estimated using the AAA average
cost-per-mile based on the average number of miles driven per year for men 55 to 64 years old
which was found to be $0.58/mile (AAA Association 2018). The AAA cost/mile was multiplied
by 22.6 miles, the median round-trip miles traveled for cancer care, totaling $18.11 per roundtrip (Longacre et al. 2019). The total transportation cost for each treatment strategy was obtained
by multiplying the number of visits associated with each strategy by the average cost per roundtrip.
The median age of patients in the Kishan et al. study (2018) was 61 years and the value
of patients’ time lost from productive work or leisure was determined from the median hourly
wage rate for men of 54 to 61 years old, assuming 40 hours/week (U.S. Bureau of Labor
Statistics 2019). The median time spent in round-trip travel for any treatment-related visit was
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40.6 minutes based on a study evaluating the travel distance to cancer-care facilities among rural
and urban cancer patients (Longacre et al. 2019). The time that was allotted for the each of the
various types of treatment-related visits were obtained from the literature or based on expert
opinion and included the following: any initial physician consultation, 1 hour; post-operative
visit, 0.5 hour; total brachytherapy procedure time, 6 hours; RALP hospital admission, 13.6
hours calculated from 1.7 days mean length of stay with 8 hours per day assumed to be lost from
work or leisure (Yu et al. 2012; Weinstein, Siegel, Gold, Kamlet, and Russell 1996). The time
lost from work or leisure associated with convalescence from brachytherapy and RALP
procedures were 3 days and 42 days at 8 hours per day, respectively (Mechow et al. 2018;
UCLA Health 2020).

Health State Utilities
Patient preferences for health states associated with organ-confined and metastatic
prostate cancer were obtained from the literature and were elicited from members of the general
public using standard gamble techniques (Stewart, Lenert, Bhatnagar, and Kaplan 2005). The
disutility associated with potential late complications of each treatment modality was not
evaluated since the probability of late complications remains unclear in the era of modern
prostate cancer treatment modalities and was not modelled (Yu and Hamstra 2017). The utility
values for the AWDM and AWODM health states are shown in Table 1.

Cost-Effectiveness Analysis
Expected costs and QALYs were calculated for each treatment strategy. The ICER was
obtained by dividing the incremental cost of the more expensive strategy by its incremental
benefit in QALYs. A three percent annual discount rate was used for costs and benefits to foster
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comparability of the results with those of many other economic evaluations (Muennig 2008). As
recommended by Neumann, Cohen, and Weinstein (2014), willingness-to-pay values of $50,000,
$100,000, and $200,000 per additional QALY gained were considered as thresholds for costeffectiveness.

Sensitivity Analyses
Deterministic sensitivity analyses were carried out to evaluate the effect of plausible
changes in key variables on the ICER, including costs, health state utility values, annual discount
rate and the probabilities of distant metastasis, prostate cancer-specific mortality, and other-cause
mortality. Probabilistic sensitivity analysis was conducted using Monte Carlo simulation on all
parameters, which were randomly and simultaneously sampled from defined probability
distributions over 1,000 iterations. Sampling from Beta distributions, mortality, and distant
metastases probabilities were varied by their reported 95 percent confidence intervals while
health state utility values were studied over their reported standard deviations. Direct costs of
RALP and all radiotherapy treatment programs were varied by plus or minus 25 percent to
approximate two standard deviations and a normal distribution was used because these were
based on solid estimates obtained from Medicare reimbursement (Singer 2006). The costs of
managing metastatic disease were Medicare estimates obtained using a decision analytic model
with a higher degree of uncertainty. Therefore, these costs were doubled and halved to
approximate a wider confidence interval and a Gamma distribution was used with standard
deviation of (high value-low value)/4 (Singer 2006).

RESULTS
Model Validation
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The results generated by the model were found to accurately mirror the five- and ten-year
distant metastasis, prostate cancer-specific survival and other-cause mortality risks reported by
Kishan et al. (2018).

Base Case Analysis
The results of the base case analysis are shown in Table 8. EBRT plus brachytherapy
resulted in a net savings of $12,262 and $31,989 versus EBRT monotherapy and RALP,
respectively. This reflects the higher upfront costs associated with RALP and the discounted
savings due to lower cumulative costs to manage progressive metastatic disease for the EBRT
plus brachytherapy group compared to the other strategies. EBRT + brachytherapy yielded an
incremental 1.30 and 1.12 QALYs over EBRT monotherapy and RALP, respectively. EBRT +
brachytherapy was both cost-saving and more effective than both EBRT monotherapy and RALP
and therefore, strongly dominated both alternative treatment strategies.
Sensitivity Analysis
The results of the one-way deterministic sensitivity analysis are illustrated in the tornado
diagrams shown in Figure 2. Tornado diagrams are graphical representations of all one-way
sensitivity analyses results for all the variables studied, presented in one figure. The gray vertical
line shows the base case ICER. The horizontal bars represent the ICER values over the range of
the variable values studied. The ICER for EBRT plus brachytherapy was most sensitive to the
total direct costs associated with the AWDM health state. However, regardless of society’s
willingness-to-pay for an additional QALY gained, EBRT plus brachytherapy strongly
dominated both competing strategies on deterministic sensitivity analysis of all key variables
over plausible ranges.
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The result of the probabilistic sensitivity analysis is illustrated in the cost-effectiveness
acceptability curve (Figure 3). An acceptability curve illustrates the percentage of Monte Carlo
simulations that each treatment strategy is preferred over the others at a certain societal
willingness-to-pay for an additional QALY. For the ten-year time horizon EBRT plus
brachytherapy was expected to be the optimal and preferred strategy in 99% of the simulations at
a willingness-to-pay of $50,000/QALY.

DISCUSSION
Cost-effectiveness analysis provides the framework for an evidence-based approach to
the comparison of the costs and quality-of-life adjusted clinical outcomes of the three modern
treatment programs for very high-risk prostate cancer. Through the use of sensitivity analysis, it
also allows the investigator to evaluate the base case results over a wide range of assumptions,
which may confirm or lead to modifying the base case conclusions. Using the actual follow up
interval reported in the Kishan et al. (2018) multi-institutional study, it was found that EBRT
plus brachytherapy saved costs, improved quality-of-life adjusted survival, and strongly
dominated its comparator treatment paradigms of EBRT monotherapy and RALP. This
conclusion was supported by the results of the probabilistic sensitivity analysis, which found
EBRT plus brachytherapy to be the preferred treatment strategy in 99 percent of the simulations
at a willingness-to-pay threshold of $50,000/QALY. This suggests that there is a high likelihood
that EBRT plus brachytherapy either dominates its comparators or is cost-effective over a tenyear time horizon. Deterministic sensitivity analysis also demonstrated that the model was most
sensitive to total direct costs associated with the management of distant metastatic disease
highlighting the importance of the reduced risk of distant metastasis seen with the EBRT plus
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brachytherapy cohort despite similar overall (all-cause) survival of the three treatment cohorts at
ten years.
The policy implications of this study are not insignificant. There are approximately
200,000 new cases of prostate cancer diagnosed annually in the United States and nearly 1.3
million globally (American Cancer Society 2020; Rawla 2019). About 20,000 and 130,000 of
these cases are expected to be very high risk in the US and worldwide, respectively (Kishan
2018). Based on the results of this cost-effectiveness analysis and considering the proportional
usage of RALP versus EBRT reported by Kishan et al. (2018), the use of EBRT plus
brachytherapy in this cohort could decrease US health care expenditures by about $431 million
annually. Annual global health care expenditures could potentially be reduced over a range of
about $16 billion to $42 billion, depending on the existing worldwide treatment mix of EBRT
monotherapy and RALP for very high-risk prostate cancer, which is not well known.
There are no other studies that have evaluated the cost-effectiveness of EBRT plus
brachytherapy versus EBRT monotherapy and RALP for organ-confined, very high-risk prostate
cancer. However, Parikh and Sher (2012) developed a decision model to analyze the comparative
effectiveness of primary radiotherapy versus radical prostatectomy for patients with high-risk
prostate cancer. They evaluated the difference in QALYs associated with three treatment
cohorts: EBRT with androgen deprivation therapy, prostatectomy plus adjuvant EBRT, and
trimodality therapy consisting of radical prostatectomy, adjuvant EBRT and androgen
deprivation therapy. Using a lifetime horizon, they found that EBRT with androgen deprivation
therapy may be superior to radical prostatectomy plus adjuvant EBRT and that trimodality
therapy may lower risks of progressive disease for a significant number of men. However, this
study also included patients with Gleason score 8 disease, consistent with a high-risk group but
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not the very high-risk group. The investigators did not discount future health benefits to their
present value and neither evaluated treatment-related costs nor the potential impact of
brachytherapy on the results.
The current cost-effectiveness analysis being presented has some limitations. First,
although others have compared the outcomes of the three treatments that were studied, a decision
was made to use mortality and distant metastasis data from one large multi-institutional
retrospective cohort study. In another retrospective cohort study, Ennis, Hu, Ryemon, Lin, and
Mazumdar (2018) assessed the overall survival of high-risk patients treated by radical
prostatectomy, EBRT with androgen deprivation therapy, and EBRT plus brachytherapy with or
without androgen deprivation therapy using the National Cancer Database. After adjusting for
prostate cancer prognostic factors, other competing medical comorbidities and socioeconomic
characteristics, these investigators found EBRT monotherapy to be associated with inferior
overall survival but there was no statistical difference in overall survival between the EBRT plus
brachytherapy and radical prostatectomy cohorts. These results are comparable to those of
Kishan et al. (2018), which showed an overall survival advantage for EBRT + brachytherapy
before 7.5 years of follow up but similar overall survival for all three treatment cohorts at ten
years, possibly reflecting an early prostate cancer-specific mortality advantage for EBRT plus
brachytherapy that eventually was trumped by increasing other-cause mortality in later years.
However, Ennis et al. (2018) did not limit their analysis to the Gleason score 9-10 very high-risk
group and did not present data on prostate-cancer-specific mortality or the risk for development
of distant metastases. These omissions provided additional support for the sole use of the Kishan
et al. (2018) study, which also utilized patient-level data.
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Second, the distant metastases, prostate cancer-specific mortality and other-cause
mortality data reported by Kishan et al. (2018) was limited to ten years and this costeffectiveness analysis was therefore, limited to this time horizon (Levine et al. 2007). Although a
lifetime horizon was not evaluated in this cost-effectiveness analysis at this time, the fact that
there are no anticipated dramatic differences in downstream costs or quality-of-life effects
indicates that the base case results are unlikely to change over longer time horizons. Despite the
fact that the overall survival of EBRT plus brachytherapy and RALP equalized by ten-years, the
significant difference in the risk of distant metastases between the EBRT plus brachytherapy
group compared to the other two treatment groups remained robust and review of the KaplanMeier curves shows this difference to continue to widen over time (Kishan et al 2018). Since the
cost of managing distant metastatic disease appears to have one of the largest relative impacts on
cost-effectiveness, it seems likely that the strategy of EBRT plus brachytherapy would only
become increasingly preferred over the other treatment options over a lifetime horizon.
Third, there was some uncertainty surrounding the costs used in the model. The direct
medical costs for EBRT plus brachytherapy, EBRT monotherapy, adjuvant/salvage EBRT after
RALP and androgen deprivation therapy were calculated using a micro-costing approach using
the Centers for Medicare and Medicaid Services Physician Fee Schedule, a well-established
source with a high degree of certainty. Similarly, the direct medical costs associated with the
AWODM health state for RALP were based on Medicare reimbursement. However, the costs
associated with the AWDM for all treatment groups were obtained from a costing study using
deterministic decision analytic techniques. Despite reporting Medicare estimates for the cost of
managing distant metastatic disease, it is possible that this study could have a higher degree of
uncertainty. To address this uncertainty, a wider confidence interval was used for sensitivity
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analysis of these costs and, despite this, the ICER for EBRT plus brachytherapy never became a
positive number.
CONCLUSION
Using the actual follow-up interval reported by Kishan et al. (2018), EBRT plus
brachytherapy strongly dominated the strategies of EBRT monotherapy and RALP for patients
with very high-risk prostate cancer. Since the long-term incremental costs and distant metastases
risks are unlikely to dramatically change after a decade of follow-up, it is likely that EBRT plus
brachytherapy will either dominate the comparator strategies or remain cost-effective given
contemporary willingness-to-pay thresholds of $50,000-$200,000 per QALY over a lifetime
scenario.
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Figure 1. Decision Tree with three embedded Markov models for EBRT + brachytherapy, EBRT
monotherapy, and RALP. Abbreviations: EBRT: external beam radiotherapy monotherapy;
EBRT+BT: external beam radiotherapy with brachytherapy boost; RALP: robotic assisted
laparoscopic prostatectomy.
20

Table 1. Model Parameters, Ranges Studied and Distributional Assumptions
Probability
Base
Distribution Reference
Case
Range
for PSA
Number
Treatment
Interval Value Studied*
Standard
Cohort
(years) (mean)
Deviation
Distant Metastasis
RALP
0-5
0.24
0.19-0.30
0.028
>5-10
0.46
0.38-0.54
0.04
EBRT
0-5
0.24
0.20-0.28
0.02
Beta
8
>5-10
0.44
0.38-0.50
0.03
EBRT+BT
0-5
0.08
0.05-0.11
0.015
>5-10
0.13
0.09-0.17
0.02
Prostate Cancer Specific Mortality
RALP
0-5
0.12
0.08-0.17
0.023
>5-10
0.23
0.18-0.30
0.03
EBRT
0-5
0.13
0.08-0.19
0.028
Beta
8
>5-10
0.26
0.20-0.32
0.03
EBRT+BT
0-5
0.03
0.01-0.05
0.01
>5-10
0.13
0.08-0.19
0.028
Death from Other Causes
RALP
0-5
0.05
0.04-0.06
0.05
>5-10
0.09
0.07-0.11
0.01
EBRT
0-5
0.05
0.04-0.06
0.05
Beta
8
>5-10
0.13
0.10-0.16
0.04
EBRT+BT
0-5
0.07
0.05-0.09
0.01
>5-10
0.18
0.14-0.24
0.025
Health State Utility Values
Alive with
Distant
Disease
0.25
0.14-0.36
0.11
Beta
22
Alive
without
distant
disease
0.81
0.63-0.99
0.18
Annual Discount Rate
Rate
0.03
0.005-0.05
Uniform
13
Abbreviations: RALP, Robotic-assisted laparoscopic prostatectomy; EBRT, external beam
radiotherapy; EBRT + BT, external beam radiotherapy with brachytherapy boost; PSA,
Probabilistic Sensitivity Analysis. *95% confidence interval when provided.
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Table 2. Direct Medical Costs of External Beam Radiotherapy Monotherapy3
2019 CMS
physician fee
schedule
Medicare
National
CPT
No.
Payment
Reimbursement Reimbursement
Service
code
Units Amount, US $ per unit, US $
Total, US $
Initial New Patient
office visit167.09*
comprehensive
99204 1
132.09**
147.14
147.14
Physician
Prescription
Treatment Plan;
Complex
77263 1
174.31
174.31
174.31
Special Treatment
77470 1
136.78
136.78
136.78
IMRT PlanIncluding DVH for
Target & Critical
Structures
77301 1
1,949.20
1,949.20
432.71
IMRT Multi-Leaf
Collimator
77338 1
497.31
497.31
497.31
Basic Dosimetry
calculation
77300 2
67.85
67.85
135.70
IMRT Treatment
delivery- single or
multiple fields
G6015 20
369.92
369.92
7,398.40
Daily CT imageguidance
77014 20
124.51
124.51
2,490.20
Radiation Treatment
Management
(weekly physician
on-treatment visit)
77427 4
196.33
196.33
785.32
Continuing physics
consultation
77336 4
81.20*
81.20
139.66
Total Direct Medical Cost for EBRT Monotherapy
13,854
Abbreviations: EBRT, external beam radiotherapy; IMRT, image-guided intensity modulated
radiotherapy; DVH: dose volume histogram.
*fee for freestanding facilities (43% of radiotherapy centers)26
**fee for hospital-based facilities (57% of radiotherapy centers)26

22

Table 3. Direct Medical Costs of External Beam Radiotherapy + Brachytherapy Boost 3
2019 CMS
Physician Fee
Schedule Medicare
National Payment
Amount, US $
167.09*
132.09**

CPT
No.
Reimbursement Reimbursement Total,
Service
code
Units
per unit, US $
US $
Initial New Patient Office
Visit-comprehensive
99204 1
147.14
147.14
Physician Prescription
Treatment Plan; Complex
77263 1
174.31
174.31
174.31
Special Treatment
77470 1
136.78
136.78
136.78
IMRT Plan-Including
DVH for Target & Critical
Structures
77301 1
1,949.20
432.71
432.71
IMRT Multi-Leaf
collimator
77338 1
497.31
497.31
497.31
Basic Dosimetry
calculation
77300 1
67.85
67.85
67.85
IMRT treatment deliverysingle or multiple fields
G6015 15
369.92
369.92
5,548.80
Daily CT image-guidance 77014 15
124.51
124.51
1,867.65
Radiation Treatment
Management (weekly
physician on-treatment
visit)
77427 3
196.33
196.33
588.99
Continuing physics
consultation
77336 3
81.20*
81.20
104.75
Total for EBRT Component
11,082.78
Simulation; 3-Dimensional
HDR
77295 1
498.04
498.04
Remote afterload HDR
77772 1
922.45
922.45
Simulation; simple
77280 1
283.30
283.30
Transperineal placement,
needle/catheters into
Prostate
55875 1
801.19
801.19
Treatment device; simple
77332 1
48.36
48.36
Hospital Outpatient and
Ambulatory Surgery
Center Facility Fee§
1
2,967
2,967
Total for Single brachytherapy HDR Implant
5,520
Total Direct Medical Cost of EBRT plus brachytherapy boost
16,603
Abbreviations: EBRT, external beam radiotherapy; IMRT, image-guided intensity modulated radiotherapy;
DVH: dose volume histogram; HDR, High Dose Rate brachytherapy. *Fee for freestanding facilities (43% of
radiotherapy centers).26 **Fee for hospital-based facilities (57% of radiotherapy centers).26 §50% Hospital
Outpatient/50% Ambulatory Surgery Centers rates6
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Table 4. Direct Medical Cost of Androgen Deprivation Therapy per 6-Month Markov Cycle3
Service
CPT code No. Units/
2019 CMS Physician
Reimbursement
6-month
Fee Schedule Medicare
Total, US $
Cycle
National Payment
Amount/unit, US $
Drug cost of leuprolide

Hormone antineoplastic
subcutaneous or
intramuscular injections
(administration of drug)

HCPCS
code
J9217

6

235.37

96402
2
32.12
Total Cost of Androgen Deprivation Therapy per 6-Month Markov Cycle

1,412.22

64.24
1,476
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Table 5. Direct Medical Costs of Adjuvant/Salvage EBRT (42.8% of RALP Group) 3
2019 CMS
physician fee
schedule
National
Payment
CPT
No.
amount, US
Reimbursement Reimbursement
Service
code
Units $
per unit, US $
Total, US $
Initial New Patient
Office Visit167.09*
comprehensive
99204 1
132.09**
147.14
147.14
Physicians
Prescription Treatment
Plan; Complex
77263 1
174.31
174.31
174.31
Special Treatment
77470 1
136.78
136.78
136.78
IMRT Plan-including
DVH for Target and
Critical Structures
77301 1
1,949.20
1949.20
1,949.20
IMRT Multi-Leaf
Collimator
77338 1
497.31
497.31
497.31
Basic Dosimetry
Calculation
77300 2
67.85
67.85
135.70
IMRT Treatment
delivery- single or
multiple fields
G6015 35
369.92
369.92
12,947.20
Daily CT ImageGuidance
77014 35
124.51
124.51
4,257.85
Radiation Treatment
Management (weekly
physician on-treatment
visit)
77427 7
196.33
196.33
1,374.31
Continuing Physics
Consultation
77336 7
81.20*
81.20
244.41
Total Direct Medical Costs for Adjuvant/Salvage EBRT
21,964
Abbreviations: EBRT, external beam radiotherapy; IMRT: image-guided intensity modulated
radiotherapy; DVH: dose volume histogram RALP, robotic-assisted laparoscopic
prostatectomy. *Fee for freestanding facilities (43% of radiotherapy centers).26 **Fee for
hospital-based facilities (57% of radiotherapy centers).26
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Table 6. Total Direct Medical Costs of the Alive With Distant Metastases Health State
per 6-Month Markov Cycle
References
Cost per 6-month
% of Total
Markov Cycle,
Cost
Adjusted to 2019 US $*
Castrate Naïve Disease
94.25
1,535
Castrate Resistant Disease
5.75
61,053
5, 19
Weighted 6-month Markov Cycle Cost
5,053
*Adjusted from 2018 to 2019 US dollars using the medical care component of the US Chained
Consumer Price Index.24
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Table 7. Direct Non-Medical Costs: Value of Patients’ Time Lost From Work or Leisure and Transportation Expenses
EBRT Monotherapy
EBRT + Brachytherapy
RALP
Adjuvant or Salvage
EBRT

Androgen Deprivation
Therapy per 6 Month
Markov Cycle^

Value of Patient
Time Lost
Hours/
Unit

No.

Cost
US$§

Hours/
Unit

No.
Units

Cost
US$§

Hours/
Unit

No.
Units

Cost US$§

Hours/
Unit

No.
Units

Cost
US$§

Hours/
Unit

No.
Units

Cost
US$§

Initial Physician
Consultation
1
1
28.43
1
1
28.43
1
1
28.43
1
1
28.43
Daily EBRT
Treatments or
Office Visit
0.5
20
284.25
0.5
15
213.19
0.5
35
497.53
0.5
2
28.43
Pre-operative Visit
1
1
28.43
1
1
28.43
Brachytherapy
Procedure
6
1
170.58
Post-Operative
Visit
0.5
1
14.21
0.5
1
14.21
Mean Hospital
Length of Stay*
8
1.7
386.58
Mean Time Out of
Work**
8
3
682.20
8
42
9,550.80
Travel Time10
0.667
21
398.15
0.667
19
360.23
0.667
4**
75.84
0.667
36
682.66
0.667
2
37.93
Total
710.83
1,497.27
10,084.29
1,208.62
66.36
Transportation
Expenses
Office or hospital
visits
21
380.31
19
344.09
4
72.44
36
651.96
2
36.22
Total Direct NonMedical Costs
1,091
1,841
10,157
1,861
103
Abbreviations: EBRT, external beam radiotherapy; RALP, robotic-assisted laparoscopic prostatectomy. §Median gender-specific wage rate is $28.43/hour.25; ^ EBRT
monotherapy and EBRT + brachytherapy patients received a total of 24 months of androgen deprivation therapy.15 Adjuvant or salvage EBRT patients received 6
months of ADT.15 * Mean hospital length of Stay for RALP was 1.7 days and assumed 8 hours/day lost from work or leisure. 29 **Assumed to be 8 hours/day of
convalescence (3 days for brachytherapy and 42 days for RALP)12,23 **Includes roundtrip to hospital for RALP.
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Table 8. Base Case Results

Cost, US $
Incremental Cost, US $
Effectiveness
Incremental
Effectiveness
Incremental CostEffectiveness Ratio
(ICER)
Interpretation

EBRT +
Brachytherapy
29,414
0
5.85

Strategies
EBRT
Monotherapy
41,676
12,262
4.54

61,403
31,989
4.73

0

-1.30

-1.12

RALP

0

-9,399
-28,575
Strongly dominated
Strongly dominated
by EBRT + BT
by EBRT + BT
Abbreviations: EBRT, external beam radiotherapy; RALP, robotic-assisted laparoscopic
prostatectomy.
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A.

B.

Figure 2. Tornado diagrams of one-way deterministic sensitivity analysis of key variables for A.)
EBRT + Brachytherapy versus EBRT monotherapy and, B.) EBRT + Brachytherapy versus RALP.
Abbreviations: EBRT: external beam radiotherapy monotherapy; EBRT+BT: external beam
radiotherapy with brachytherapy boost; RALP: robotic assisted laparoscopic prostatectomy; EV:
expected value
29

Figure 3. Cost-effectiveness acceptability curve for EBRT, EBRT+ BT, and robotic assisted
laparoscopic radical prostatectomy at a willingness-to-pay of $50,000 to $200,000/QALY.
Abbreviations: EBRT: external beam radiotherapy monotherapy; EBRT+BT: external beam
radiotherapy with brachytherapy boost
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